Indinavir sulfate en es it fr

Categoria

Indinavir sulfate Marchi, Indinavir sulfate Analoghi

Indinavir sulfate Marchi miscela

  • No information avaliable
  • Indinavir sulfate Formula chimica

    C36H47N5O4

    Indinavir sulfate RX link

    http://www.rxlist.com/cgi/generic2/indinav.htm

    Indinavir sulfate FDA foglio

    Indinavir_sulfate FDA

    Indinavir sulfate DMS (foglio di materiale di sicurezza)

    Indinavir_sulfate MSDS

    Indinavir sulfate Sintesi di riferimento

    JP Vacca et al USPat. 5,413,999 (1995)

    Indinavir sulfate Peso molecolare

    613.79 g/mol

    Indinavir sulfate Temperatura di fusione

    167.5-168 oC

    Indinavir sulfate H2O Solubilita

    0,015 mg / ml

    Indinavir sulfate Stato

    Solid

    Indinavir sulfate LogP

    2.569

    Indinavir sulfate Forme di dosaggio

    Capsule orali

    Indinavir sulfate Indicazione

    Per il trattamento dell'infezione da HIV.

    Indinavir sulfate Farmacologia

    Indinavir è un inibitore della proteasi con attività contro il virus dell'immunodeficienza umana di tipo 1 (HIV-1). Inibitori della proteasi blocco da parte di HIV proteasi chiamata. Proteasi dell'HIV-1 è un enzima necessario per la la segmentazione proteolitica dei precursori poliproteici virale nelle singole proteine funzionali si trovano in infettive da HIV-1. Indinavir si lega al sito attivo della proteasi e inibisce l'attività di l'enzima. Questa inibizione impedisce la segmentazione del poliproteine virale causando la formazione di particelle virali immature non infettive. Inibitori della proteasi sono quasi sempre utilizzati in combinazione con almeno altri due farmaci anti-HIV.

    Indinavir sulfate Assorbimento

    Rapidamente assorbito

    Indinavir sulfate Tossicita

    Sintomi di sovradosaggio includono infarto miocardico e angina pectoris.

    Indinavir sulfate Informazioni paziente

    A statement to patients and health care providers is included on the product’s bottle label. ALERT: Find out about medicines that should NOT be taken with CRIXIVAN. A Patient Package Insert (PPI) for CRIXIVAN is available for patient information.

    CRIXIVAN is not a cure for HIV infection and patients may continue to develop opportunistic infections and other complications associated with HIV disease. The long-term effects of CRIXIVAN are unknown at this time. CRIXIVAN has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.

    Patients should be advised to remain under the care of a physician when using CRIXIVAN and should not modify or discontinue treatment without first consulting the physician. Therefore, if a dose is missed, patients should take the next dose at the regularly scheduled time and should not double this dose. Therapy with CRIXIVAN should be initiated and maintained at the recommended dosage.

    CRIXIVAN may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John’s wort.

    For optimal absorption, CRIXIVAN should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, CRIXIVAN may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar. Ingestion of CRIXIVAN with a meal high in calories, fat, and protein reduces the absorption of indinavir.

    Patients receiving a phosphodiesterase type 5 (PDE5) inhibitor (sildenafil, tadalafil, or vardenafil) should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events including hypotension, visual changes, and priapism, and should promptly report any symptoms to their doctors.

    Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

    CRIXIVAN Capsules are sensitive to moisture. Patients should be informed that CRIXIVAN should be stored and used in the original container and the desiccant should remain in the bottle.

    Indinavir sulfate Atto interessato organismi

    Virus dell'immunodeficienza umana